Immune cell boost may help kids beat Post-Transplant viruses

NCT ID NCT07225972

Not yet recruiting Disease control Sponsor: New York Medical College Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding immune cells from a family donor to standard antiviral drugs can help children and young adults clear stubborn adenovirus or cytomegalovirus infections after a stem cell transplant. About 69 participants will be randomly assigned to receive either the immune cells plus standard care or standard care alone. The goal is to see if the added cells help the body fight the virus better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Family donor-derived viral-specific cytotoxic T lymphocytes (CTLs) plus standard antiviral medications
What this could lead to: If it works, this could offer a new way to treat hard-to-clear viral infections after stem cell transplant, potentially reducing serious complications.
What could go wrong: This is a small early-stage trial (69 participants) and the added immune cells may not work for everyone or could cause side effects like graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOVIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoviridae infectious disease cytomegalovirus infection infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOVIRUS ADV INFECTION ADV REACTIVATION CMV CYTOMEGALOVIRUS INFECTIONS

More trials for these conditions

Other studies related to the condition(s) this trial covers.